ZLNA – Issuance of shares through set-off of option exercise fee

Core Points - Zelluna ASA's Annual General Meeting authorized the Board of Directors to issue new shares at a subscription price of NOK 26 to settle an option exercise fee of EUR 500,000 to Inven2 [1] - The Board has resolved to issue 227,096 new shares to Inven2 in exchange for the aforementioned amount [1] Company Overview - Zelluna ASA aims to provide transformative treatments for advanced solid cancers in a safe and cost-efficient manner globally [2] - The company focuses on developing "off the shelf" T cell receptor (TCR) guided natural killer (NK) cell therapies, which offer a unique mechanism of action for broad cancer detection [2] - The lead program targets MAGE-A4 with the world's first "off the shelf" TCR-NK therapy for various solid cancers, with additional products in the pipeline [2] - The management team consists of biotech entrepreneurs with extensive experience in the discovery and clinical development of TCR and cell-based therapies [2]